PDX model details
| PDX ID |
374M Cx |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Castrate |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
21 (13*) |
| Average PDX Generation Time (days +/- SEM) |
56 ± 4 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen or cryopreserved tissue) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
374M Cx |
| AR |
N |
| PSA |
N |
| PSMA |
N |
| NE |
Y |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 374M Cx |
SPEN |
0.563 |
2.954 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
SETDB1 |
0.770 |
3.409 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
AKT3 |
0.770 |
3.411 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
FANCD2 |
0.578 |
2.986 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
BRAF |
0.528 |
2.884 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
EZH2 |
0.528 |
2.884 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
KMT2C |
0.528 |
2.884 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
AXIN2 |
0.596 |
3.023 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
PIK3R2 |
0.708 |
3.268 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
MET |
0.528 |
2.884 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
MYC |
3.582 |
23.954 |
Gain-High
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
PTEN |
-22.993 |
2.400e-07 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
ZFHX3 |
-26.976 |
1.520e-08 |
Homdel
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 374M Cx |
RB1 |
-1.277 |
0.825 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
374M |
| Sample Site |
Liver |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT |
| |
|
Patient Information
| Patient Number |
374 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 374M Cx |
ERBB4 |
376 |
1.0 |
Missense variant |
'23/28 |
. |
27 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 374M Cx |
TP53 |
422 |
0.97 |
Frameshift variant |
'5/11 |
. |
. |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 374M Cx |
TH |
495 |
0.44 |
Missense variant |
'8/14 |
. |
15.88 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 374M Cx |
FANCL |
604 |
0.31 |
Missense variant |
'1/14 |
. |
25.8 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 374M Cx |
GATA2 |
594 |
0.28 |
Missense variant |
'3/6 |
. |
21.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 374M Cx |
MGAM |
847 |
0.27 |
Missense variant |
'16/48 |
. |
23.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Gene expression
No information in Drug dosing Table